Development of the proteasome inhibitor Velcade™ (Bortezomib) by Julian!Adams, Ph.D., and Michael!Kauffman, MD, Ph.D.

被引：20

作者：

Bold, R ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Med, Div Surg Oncol, Sacramento, CA 95817 USA

来源：

CANCER INVESTIGATION | 2004年 / 22卷 / 02期

关键词：

D O I：

10.1081/CNV-120030223

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：328 / 329

页数：2

共 5 条

[1]

Proteasome inhibition: A novel mechanism to combat asthma [J].

Elliott, PJ ;

Pien, CS ;

McCormack, TA ;

Chapman, ID ;

Adams, J .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (02) :294-300

[2]

Kawakami A, 1999, ARTHRITIS RHEUM, V42, P2440, DOI 10.1002/1529-0131(199911)42:11<2440::AID-ANR23>3.0.CO

[3]

2-0

[4]

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin [J].

Masdehors, P ;

Omura, S ;

Merle-Béral, H ;

Mentz, F ;

Cosset, JM ;

Dumont, J ;

Magdelénat, H ;

Delic, J .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (03) :752-757

[5]

Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia [J].

Zhang, L ;

Zhang, ZG ;

Zhang, RL ;

Lu, M ;

Adams, J ;

Elliott, PJ ;

Chopp, M .

STROKE, 2001, 32 (12) :2926-2931

← 1 →